Deutsche Bank Maintains a 'Hold' on Amgen (AMGN); Legacy Business and Prolia Show Signs of Life
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $436.43 -1.34%
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
20 Buy, 18 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Deutsche Bank maintains a 'Hold' on Amgen (NASDAQ: AMGN) price target of $84.00 (from $72.00).
Analyst, Robyn Karnauskas, said, "In terms of legacy products, Epogen, Aranesp, Neupogen, Enbrel & Sensipar all beat expectations. Epogen ($525M vs. $447M consensus) & Enbrel ($1,058M vs. $962M consensus) were especially strong. The Dmab franchise also posted a solid Q2 driven by a Prolia beat by $20M ($120M vs. $100M consensus). This all led to beat on product sales beat by $200M & EPS by $0.30 ($1.83 vs. $1.53)...Pipeline is emerging – We like AMG785, AMG145 & brodalumab – All upside."
Raising FY12 EPS estimates and revenues.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $79.30 yesterday.
Analyst, Robyn Karnauskas, said, "In terms of legacy products, Epogen, Aranesp, Neupogen, Enbrel & Sensipar all beat expectations. Epogen ($525M vs. $447M consensus) & Enbrel ($1,058M vs. $962M consensus) were especially strong. The Dmab franchise also posted a solid Q2 driven by a Prolia beat by $20M ($120M vs. $100M consensus). This all led to beat on product sales beat by $200M & EPS by $0.30 ($1.83 vs. $1.53)...Pipeline is emerging – We like AMG785, AMG145 & brodalumab – All upside."
Raising FY12 EPS estimates and revenues.
For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.
Shares of Amgen closed at $79.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Marti Technologies (MRT) PT Raised to $6 at Benchmark on Stronger Growth, Improved Earnings Visibility
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
